Hetero Labs Limited - Unit III – FDA 483, Jun 7, 2019
Hetero Labs, Ltd. - Unit III, a finished dosage drug manufacturer in Hyderabad, India, was cited for significant deficiencies across its quality systems. The inspection revealed widespread issues including inadequate computer system controls, lack of written procedures for critical manufacturing processes, insufficient investigations into discrepancies, and failures in laboratory instrument calibration and sample management. These observations indicate a systemic lack of control over manufacturing and quality operations, posing a high risk to product quality and data integrity.
ID · 36e5da2c-e813-4ebd-a09d-d5e8f71f6cd7
- 483 - 2025-09-26
- 483 - 2023-07-21
- 483 - 2018-10-26
- 483 - 2018-03-23
- 483 - 2016-10-26
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.